Venturepharm Group Revenue and Competitors
Estimated Revenue & Valuation
- Venturepharm Group's estimated annual revenue is currently $12.4M per year.
- Venturepharm Group's estimated revenue per employee is $243,000
Employee Data
- Venturepharm Group has 51 Employees.
- Venturepharm Group grew their employee count by 2% last year.
Venturepharm Group's People
Name | Title | Email/Phone |
---|
Venturepharm Group Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $66.2M | 223 | 20% | N/A | N/A |
#2 | $7.3M | 34 | 6% | N/A | N/A |
#3 | $217.7M | 645 | 27% | N/A | N/A |
#4 | $129.6M | 384 | 10% | N/A | N/A |
#5 | $15.1M | 62 | 22% | N/A | N/A |
#6 | $42.8M | 144 | 15% | N/A | N/A |
#7 | $110.8M | 323 | 13% | $117M | N/A |
#8 | $103.2M | 301 | 2% | $440.7K | N/A |
#9 | $107.3M | 318 | 10% | N/A | N/A |
#10 | $46.9M | 158 | 34% | N/A | N/A |
What Is Venturepharm Group?
Company introduction: Venturepharm group is an Asia based, life science leader with principal activities in an most affordable world-class innovative full service plus model from venture capital, merchant banking, CRO, CMO, CSO, compound partnering to royalty sharing. Venturepharm engages in strategic licensing of therapeutic compound pipelines, and markets projects to China, an emerging global top five market. Two of the flagships from the group are public trade companies: -Venturepharm Lab (HK stock exchange 8225), China's largest full-service CRO - Commonwealth Biotechnologies, Inc (NASDAQ: Capital market “CBTEâ€), The group now operates Eight distinct business units with over 4500 employees worldwide:
keywords:N/AN/A
Total Funding
51
Number of Employees
$12.4M
Revenue (est)
2%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $7.5M | 51 | -11% | N/A |
#2 | $5.5M | 51 | 34% | N/A |
#3 | $14M | 51 | -4% | N/A |
#4 | $4.7M | 51 | 2% | N/A |
#5 | $75M | 51 | 4% | N/A |